Amphastar Pharmaceuticals (AMPH) Resumen de Acciones
Amphastar Pharmaceuticals, Inc. es una empresa biofarmacéutica que desarrolla, fabrica, comercializa y vende productos genéricos y patentados inyectables, inhalables e intranasales en Estados Unidos, China y Francia. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 2/6 |
| Salud financiera | 3/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
AMPH Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Amphastar Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$20.71 |
| Máximo en las últimas 52 semanas | US$31.26 |
| Mínimo de 52 semanas | US$16.65 |
| Beta | 0.90 |
| Cambio en 1 mes | 9.87% |
| Variación en 3 meses | 5.72% |
| Cambio de 1 año | -9.80% |
| Variación en 3 años | -64.06% |
| Variación en 5 años | 0.49% |
| Variación desde la OPV | 106.89% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 24
AMPH: Cooler Outlook And AMP-004 Uncertainty Will Shape Balanced Future Prospects
Amphastar Pharmaceuticals' analyst price target has been revised from $25.45 to $19.00 as analysts factor in updated Q1 models, a higher discount rate, more uncertain 2026 revenue expectations, and questions around AMP-004 interchangeability status. Analyst Commentary Recent research coverage on Amphastar Pharmaceuticals points to a cooler tone, with several bearish analysts trimming price targets and tempering expectations around the company’s medium term outlook.
Actualización de narrativa • Jun 09
AMPH: Updated Outlook And Q1 Reset Will Support Future Upside Potential
Amphastar Pharmaceuticals' analyst price targets have been trimmed by several firms, with the average target moving from about $26.86 to $22.83 as analysts update models following recent Q1 results, adjust revenue and margin assumptions, and highlight added uncertainty around the 2026 outlook and AMP-004. Analyst Commentary Recent research updates point to a more cautious tone around Amphastar Pharmaceuticals, with several firms trimming price targets and revisiting assumptions after the latest Q1 report and the updated 2026 outlook.
Actualización de narrativa • May 26
AMPH: Reset Expectations May Set Stage For Future Upside
Narrative Update on Amphastar Pharmaceuticals Analysts have reset Amphastar Pharmaceuticals' price target to $19 from $30. This revision reflects lower modeled revenue growth, reduced profit margin assumptions, a higher discount rate, and increased uncertainty around AMP-004's potential interchangeability status and the company's ability to meet its 2026 outlook.Recent updates
Actualización de narrativa • Jun 24
AMPH: Cooler Outlook And AMP-004 Uncertainty Will Shape Balanced Future Prospects
Amphastar Pharmaceuticals' analyst price target has been revised from $25.45 to $19.00 as analysts factor in updated Q1 models, a higher discount rate, more uncertain 2026 revenue expectations, and questions around AMP-004 interchangeability status. Analyst Commentary Recent research coverage on Amphastar Pharmaceuticals points to a cooler tone, with several bearish analysts trimming price targets and tempering expectations around the company’s medium term outlook.Actualización de narrativa • Jun 09
AMPH: Updated Outlook And Q1 Reset Will Support Future Upside Potential
Amphastar Pharmaceuticals' analyst price targets have been trimmed by several firms, with the average target moving from about $26.86 to $22.83 as analysts update models following recent Q1 results, adjust revenue and margin assumptions, and highlight added uncertainty around the 2026 outlook and AMP-004. Analyst Commentary Recent research updates point to a more cautious tone around Amphastar Pharmaceuticals, with several firms trimming price targets and revisiting assumptions after the latest Q1 report and the updated 2026 outlook.Actualización de narrativa • May 26
AMPH: Reset Expectations May Set Stage For Future Upside
Narrative Update on Amphastar Pharmaceuticals Analysts have reset Amphastar Pharmaceuticals' price target to $19 from $30. This revision reflects lower modeled revenue growth, reduced profit margin assumptions, a higher discount rate, and increased uncertainty around AMP-004's potential interchangeability status and the company's ability to meet its 2026 outlook.Artículo de análisis • May 15
There May Be Some Bright Spots In Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings
The most recent earnings report from Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) was disappointing for...Actualización de narrativa • May 10
AMPH: Buybacks And New Approvals Will Support Future Upside Potential
Narrative Update on Amphastar Pharmaceuticals The latest analyst work has trimmed Amphastar Pharmaceuticals' implied fair value to about $26.86 from $28.00, as analysts factor in recent price target cuts from multiple firms and a slightly higher discount rate tied to softer revenue guidance despite recent product approvals. Analyst Commentary Recent research on Amphastar Pharmaceuticals has turned more cautious, with multiple firms trimming price targets and one downgrade reflecting concerns around revenue guidance and execution, even as new products win approvals.Seeking Alpha • Apr 30
Amphastar: A Cheap Multiple Doing Exactly What It's Supposed To Do
Summary Amphastar Pharmaceuticals trades at a deep discount—6.7x trailing earnings—reflecting structural growth and margin challenges. Branded product growth (BAQSIMI, Primatene MIST) has not offset accelerating legacy generic erosion, resulting in flat or declining revenues. 2026 guidance has already been cut; gross margins are guided lower, and consensus estimates likely remain too high heading into Q1 earnings. I maintain a HOLD rating, leaning bearish, pending a clean AMP-007 launch or transformative business development. Read the full article on Seeking AlphaActualización de narrativa • Apr 24
AMPH: Revised Outlook Suggests Future Upside As New Therapies Scale
Narrative Update on Amphastar Pharmaceuticals The analyst price target for Amphastar Pharmaceuticals has shifted from $38 to $30 as analysts factor in revised revenue guidance, lower projected profit margins, and a higher assumed future P/E multiple. They also note the potential importance of AMP-007 for achieving mid to high single digit revenue growth targets.Actualización de narrativa • Apr 10
AMPH: Share Repurchases And New Launches Will Support Future Upside Potential
Analysts have trimmed Amphastar Pharmaceuticals' fair value estimate by $1 to about $28, reflecting lower Street price targets and cautious views on revised revenue guidance despite recent product approvals. Analyst Commentary Recent Street research on Amphastar shares points to a more cautious tone after the latest revenue guidance update and lower price targets, even as new products move through the approval pipeline.Actualización de narrativa • Mar 26
AMPH: Softer Guidance And Execution Risk Will Shape Future Upside Potential
Analysts have trimmed Amphastar Pharmaceuticals' fair value estimate from $32.00 to $29.00. This reflects updated views on softer revenue guidance, lower projected profit margins, a slightly higher discount rate, and a higher assumed future P/E multiple in light of recent price target cuts to $30.00 from several firms.Actualización de narrativa • Mar 12
AMPH: Softer Guidance And Pipeline Risk Will Still Support Future Upside
Analysts have modestly reduced their price targets on Amphastar Pharmaceuticals to $30, reflecting concerns about softer revenue guidance and pipeline execution risk. At the same time, recent product approvals and revised earnings assumptions support a slightly higher modeled fair value and P/E multiple in our framework.Actualización de narrativa • Feb 26
AMPH: Pipeline Execution Risk Will Cap Upside Despite Lowered US$30 Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31, citing cautious views on pipeline execution risk, even as they still see the shares as undervalued relative to peers and historical valuation. Analyst Commentary Recent research updates reflect a more cautious tone, with bearish analysts trimming price expectations even while acknowledging that Amphastar still trades at what they view as a discount to peers and its own history.Actualización de narrativa • Feb 09
AMPH: Pipeline Execution Risk Will Drive Cautious View Despite Lowered US$30 Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to US$30 from US$31, reflecting a cautious view on pipeline execution risk, even as they see the shares as undervalued relative to historical and peer valuations. Analyst Commentary Bearish analysts have trimmed their price target on Amphastar Pharmaceuticals to US$30 from US$31 as coverage transitions, signaling a cautious stance on how the company can deliver on its current pipeline while justifying its valuation.Actualización de narrativa • Jan 25
AMPH: Buybacks And Pipeline Risk Will Shape Cautious Yet Balanced Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31, reflecting updated views on revenue growth, margin assumptions, and future P/E expectations, along with ongoing caution around pipeline execution risk. Analyst Commentary Bearish analysts have taken a slightly more cautious stance, trimming the price target to US$30 from US$31 as coverage transitions to a new lead.Actualización de narrativa • Jan 11
AMPH: Pipeline Execution Risk Will Shape Cautious View Despite Buybacks
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31. The revised target reflects fresh coverage that balances a view of the shares as undervalued on comps and historical valuation with caution around pipeline execution risk.Actualización de narrativa • Dec 13
AMPH: Q3 Drug Trends And Buybacks Will Shape Balanced Near-Term Outlook
Analysts have modestly lowered their price target on Amphastar Pharmaceuticals to $31 from $32, citing recent Q3 pricing and volume trends for key drugs and a largely unchanged outlook for near term earnings and 2026 estimates. Analyst Commentary Bearish analysts have highlighted that the modest reduction in the price target reflects growing caution around the durability of Amphastar's recent performance, particularly in light of more muted pricing and volume trends observed in the third quarter.Artículo de análisis • Jul 01
Earnings Working Against Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Share Price
Amphastar Pharmaceuticals, Inc.'s ( NASDAQ:AMPH ) price-to-earnings (or "P/E") ratio of 7.6x might make it look like a...Artículo de análisis • Apr 04
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 19
Amphastar Pharmaceuticals: A Gradual Strategy
Summary Amphastar Pharmaceuticals has a growth model based on organic growth and acquisitions, though competition and patent expirations pose risks. Financially, Amphastar has a strong revenue trend but faces potential growth slowdowns, especially in 2025. A fair value estimate derived from a DCF model and backed by a comparison with peers is $43.24, which suggests a 40% upside. My strategy includes a 0.75x position weight and a gradual approach combining the stock with a Covered Call. Read the full article on Seeking AlphaArtículo de análisis • Jan 03
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Dec 16
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 12.9x Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) may be sending...Artículo de análisis • Nov 28
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Seeking Alpha • Oct 25
Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)
Summary Amphastar's Q2 2024 revenue grew 25% year-over-year to $182.4 million, primarily driven by BAQSIMI and Primatene MIST sales. Primatene MIST faces future challenges as its key patent expires in 2026, limiting long-term revenue potential. BAQSIMI contributed $38.5 million in Q2 2024 sales, affirming its strategic acquisition from Eli Lilly. Amphastar’s heavy reliance on a few high-margin products, like glucagon and epinephrine, may limit future growth due to rising competition. I recommend holding Amphastar as current valuations seem fair, but growth prospects are uncertain due to product competition and patent expirations. Read the full article on Seeking AlphaArtículo de análisis • Sep 15
Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Amphastar Pharmaceuticals, Inc.'s ( NASDAQ:AMPH ) price-to-earnings (or "P/E") ratio of 14.1x might make it look like a...Seeking Alpha • Sep 12
Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Summary Amphastar Pharmaceuticals has seen significant growth since its 2014 IPO, with its stock price increasing over 500% to $45 per share. The acquisition of Baqsimi from Eli Lilly is a key revenue driver, but its long-term profitability remains uncertain due to milestone payments. Amphastar's revenue growth from epinephrine and Primatene Mist may not be sustainable, and the company faces intense competition in these markets. The pipeline's future is unclear, with several FDA rejections and no standout products, leading to a "Hold" rating on Amphastar stock. Read the full article on Seeking Alpha
Nueva narrativa • Sep 10
Decisive Acquisitions And Production Innovations Propel Pharma Growth And Market Dominance
Emphasis on proprietary products and strategic acquisitions to enhance market presence and contribute significantly to revenue growth.Artículo de análisis • Aug 27
Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Artículo de análisis • Jul 05
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Jul 01
Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Summary AMPH has materially benefited from a variety of temporary factors across their key product lines that have largely gone unnoticed by investors, sending shares up ~100% over the last 3yrs. Amphastar’s glucagon business has benefited from shortages at Fresenius, which were recently rectified. Three new competitors are about to launch glucagon, turning this duopoly into a potential 5-player market. Epinephrine revenues should meaningfully disappoint as shortage benefits alleviate, a newly approved competitor ramps, and two potential competitors gain approval. The sole Orange Book patent on Primatene MIST, a key high margin product, expires in January 2026, which opens the door to material competition. Primatene is one of the few DTC products in its aisle without a generic. A handful of smaller “Other” products have been buoyed by a tornado which took out competitor Pfizer’s product warehousing. The magnitude of the benefit is larger than investors believe, and Pfizer is quickly returning to market. Read the full article on Seeking AlphaArtículo de análisis • May 30
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 17x, you may...Seeking Alpha • May 30
Amphastar Pharmaceuticals: Buy When Fear Is Overblown
Summary Seeking Alpha's screener identified Amphastar Pharmaceuticals as a potential investment candidate based on its solid financials, positive growth in revenue and earnings. Despite its strong financials and potential for earnings growth, the company's stock fell 31% in 5 months. The article aims to uncover the reasons behind the price decline to determine if the price decline is a temporary setback that offers an opportunity for value investors. Read the full article on Seeking AlphaSeeking Alpha • May 15
Reassessing Amphastar Pharmaceuticals
Summary Amphastar Pharmaceuticals, Inc. stock is down approximately 30% this year, and the company reported mixed Q1 results last week. Despite the poor performance of the stock so far in 2024, there are some positives on the company and its stock. An updated analysis around Amphastar Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • Mar 27
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Rentabilidad de los accionistas
| AMPH | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 13.0% | 9.7% | 0.3% |
| 1Y | -9.8% | 50.8% | 19.9% |
Rentabilidad vs. Industria: Los resultados de AMPH fueron inferiores a los de la industria US Pharmaceuticals, que obtuvo un rendimiento del 50.8% el año pasado.
Rentabilidad vs. Mercado: AMPH obtuvo unos resultados inferiores a los del mercado US, que fueron del 19.9% el año pasado.
Volatilidad de los precios
| AMPH volatility | |
|---|---|
| AMPH Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: AMPH no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de AMPH (9%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1996 | 1,976 | Jack Zhang | www.amphastar.com |
Amphastar Pharmaceuticals, Inc. es una empresa biofarmacéutica que desarrolla, fabrica, comercializa y vende productos genéricos y patentados inyectables, inhalables e intranasales en Estados Unidos, China y Francia. Ofrece BAQSIMI, un aerosol nasal seco utilizado en caso de emergencia para el tratamiento de la hipoglucemia grave; Primatene MIST, un producto de inhalación de epinefrina para el alivio temporal de los síntomas leves del asma intermitente; Glucagón para kit de emergencia inyectable; Enoxaparina, una forma inyectable de heparina de bajo peso molecular para la prevención y el tratamiento de la trombosis venosa profunda; y REXTOVY y Naloxona para la sobredosis de opiáceos. La empresa también suministra Cortrosyn, una potencia liofilizada para su uso como agente diagnóstico en el cribado de pacientes con insuficiencia corticosuprarrenal; Amphadase, una inyección de hialuronidasa de origen bovino; Epinefrina inyectable para reacciones alérgicas; Jalea de lidocaína, un producto anestésico para procedimientos urológicos; Solución tópica de lidocaína para diversos procedimientos; Inyección de fitonadiona, una inyección de vitamina K1 para recién nacidos; y productos para jeringuillas de emergencia, como atropina, cloruro cálcico, dextrosa, epinefrina, lidocaína y bicarbonato sódico.
Resumen de fundamentos de Amphastar Pharmaceuticals, Inc.
| Estadísticas fundamentales de AMPH | |
|---|---|
| Capitalización bursátil | US$960.34m |
| Beneficios(TTM) | US$79.23m |
| Ingresos (TTM) | US$720.53m |
11.5x
Ratio precio-beneficio (PE)1.3x
Ratio precio-ventas (PS)¿Está AMPH sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de AMPH | |
|---|---|
| Ingresos | US$720.53m |
| Coste de los ingresos | US$379.40m |
| Beneficio bruto | US$341.13m |
| Otros gastos | US$261.90m |
| Beneficios | US$79.23m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 1.80 |
| Margen bruto | 47.34% |
| Margen de beneficio neto | 11.00% |
| Ratio deuda/patrimonio | 79.0% |
¿Cómo se ha desempeñado AMPH a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/29 13:23 |
| Precio de las acciones al final del día | 2026/06/29 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Amphastar Pharmaceuticals, Inc. está cubierta por 14 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| Pavan Patel | BofA Global Research |